AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06662253
Drug: Standard of Care Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
Trial: NCT05139719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taking Placebo orally once daily, up to 24 weeks in main stage
Trial: NCT06305299
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 300 mg/m2 IV will be given.
Trial: NCT05614258
Drug: ADG206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
Trial: NCT05262595
Drug: NNC0471-0119 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Trial: NCT04840485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05262595
Drug: NNC0471-0119 B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Trial: NCT04651439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* \> 150kg = 20mL of Glucose 5% solution (by IV)
Trial: NCT04956276
Drug: ALXN1830
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an SC infusion.
Trial: NCT04956276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an SC infusion.
Trial: NCT05243524
Drug: Cyclophosphamide 50mg
RxNorm normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO BID, one week on, one week off
Trial: NCT06284590
Drug: L19IL2/L19TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.
Trial: NCT06284590
Drug: KEYTRUDA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.
Trial: NCT05813184
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any antibiotic therapy administered \> 7 days
Trial: NCT06343064
Drug: PLB1004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase Ib is a dose escalation study, the initial dose of PLB1004 is 80mg/160mg,according to the result of Phase Ib, will confirm the RP2D.
Trial: NCT06485713
Drug: trifluridine/tipiracil combined with fufuquitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trifluridine/tipiracil combined with fufuquitinib
Trial: NCT06485713
Drug: fufuquitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fufuquitinib
Trial: NCT06485713
Drug: Trifluridine/tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil
Trial: NCT05450471
Drug: Corticosteroid Topical
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
Trial: NCT04898348
Drug: KBL697
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules twice a day dosing of KBL697
Trial: NCT04898348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules twice a day dosing of Placebo
Trial: NCT04818216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule containing inert ingredient
Trial: NCT06499415
Drug: 5-FU 50 MG/ML Topical Cream
RxNorm normalized name: 5-FU 50 MG/ML Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical 5FU, twice daily, 7 days a week, during 4 weeks
Trial: NCT06658925
Drug: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
Trial: NCT05927428
Drug: BRM424 Ophthalmic Solution - Dose1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical drop of BRM424 ophthalmic solution.
Trial: NCT05927428
Drug: BRM424 Ophthalmic Solution - Dose2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical drop of BRM424 ophthalmic solution.
Trial: NCT05432596
Drug: ATI-1777 2.0% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-1777 topical solution 2.0% w/w
Trial: NCT05432596
Drug: ATI-1777 1.0% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-1777 topical solution 1.0% w/w
Trial: NCT05432596
Drug: ATI-1777 0.5% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-1777 topical solution 0.5% w/w
Trial: NCT05432596
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle topical solution
Trial: NCT05476887
Drug: KP104
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.
Trial: NCT06644833
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, SNRIs
Trial: NCT01937663
Drug: KWA-0711
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04481204
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04481204
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05542095
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
Trial: NCT05533294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline (0.9% NaCl) by sc injection
Trial: NCT05962645
Drug: Vapendavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
Trial: NCT04767581
Drug: KHK7791
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT04767581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT05073484
Drug: BAT6021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ⅳ infusions
Trial: NCT05073484
Drug: BAT1308
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ⅳ infusions
Trial: NCT06662396
Drug: MK-6552
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Gelatin Coated Capsule
Trial: NCT06422221
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
Trial: NCT06422221
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
Trial: NCT05475483
Drug: SOM3355 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be blind for the whole duration of the study.
Trial: NCT05475483
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be blind for the whole duration of the study.
Trial: NCT06034873
Drug: Propofol injection and fentanyl
RxNorm normalized name: propofol Injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
Trial: NCT06125925
Drug: Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
Trial: NCT05271253
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of normal Saline
Trial: NCT05541822
Drug: ABN401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets~Route of Administration: Oral
Trial: NCT04697537
Drug: Ultrasound guided regional anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied perineurally preoperatively ultrasound guided regional anesthesia
Trial: NCT04697537
Drug: Local infiltration analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied in the wound intraoperatively from the orthopedics
Trial: NCT04728360
Drug: BAT2206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/0.5 mL
Trial: NCT05431387
Drug: cytisinicline
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Trial: NCT05431387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablets containing matched placebo
Trial: NCT04784052
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
Trial: NCT04747054
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles
Trial: NCT06045858
Drug: Anticoagulation Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
Trial: NCT05522582
Drug: Methotrexate tablets
RxNorm normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
Trial: NCT05175430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
Trial: NCT06657885
Drug: his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48
Trial: NCT05849675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose placebo
Trial: NCT04826107
Drug: DP303c treatment（second-line of HER2-positive）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP303c injection, every 3 weeks.
Trial: NCT04826107
Drug: DP303c treatment （third-line of HER2-positive）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP303c injection, every 3 weeks.
Trial: NCT04826107
Drug: DP303c treatment（≥second-line of HER2 low expressing）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP303c injection, every 3 weeks.
Trial: NCT04826107
Drug: DP303c + PD-1/PD-L1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
Trial: NCT06279364
Drug: SKB264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT06279364
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet. Oral route of administration.
Trial: NCT04730635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose matched placebo capsule QD, orally for Days 1-56.
Trial: NCT05772455
Drug: XZB-0004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with Penpulimab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
Trial: NCT05779241
Drug: LYN-005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone long-acting oral capsule
Trial: NCT06170463
Drug: MI/DCI combination in 40:1 ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI-group received MI/DCI combination in 40:1 ratio twice daily
Trial: NCT06388148
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
Trial: NCT06659653
Drug: PRG2302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
Trial: NCT06661005
Drug: IV Sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol. A pulse oximeter will be placed and oxygen will be administered through a nasal cannula and the patient will be instructed to breath.
Trial: NCT05041907
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
Trial: NCT05041907
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40mg OD for 7/7
Trial: NCT05041907
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
Trial: NCT06285201
Drug: R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg IV of Test drug manufactured by Patheon Italia
Trial: NCT05723731
Drug: Laxative Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
Trial: NCT06209138
Drug: 5 fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
Trial: NCT04597359
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06238895
Drug: Tardyferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
Trial: NCT06019039
Drug: Normal Saline Flush
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
Trial: NCT05653310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule
Trial: NCT05594927
Drug: Huachansu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
Trial: NCT06302426
Drug: INI-4001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.
Trial: NCT04961528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days.
Trial: NCT04845659
Drug: Doptelet Pill
RxNorm normalized name: Doptelet Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
Trial: NCT05947461
Drug: 100mg diclofenac
RxNorm normalized name: diclofenac sodium 100 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
Trial: NCT05947461
Drug: 100mg indomethacin
RxNorm normalized name: indomethacin 100 MG
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
Trial: NCT04683146
Drug: Hand antisepsis with Propanolol- 1 60%.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later
Trial: NCT05389514
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.